BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that management will host a webcast and conference call for analysts and investors on Tuesday, August 12, 2025, at 4:30 p.m. ET
Related Questions
Are there any upcoming catalysts, such as conference presentations or data readouts, that could move the stock price?
Did the company disclose any partnership or licensing agreements that could impact future revenue streams?
Will there be any updates on the company's manufacturing strategy or capacity for RNA medicines?
How does the Q2 2025 performance compare to peer biotech companies developing RNA therapeutics?
How does the current valuation (e.g., EV/Revenue, P/E) compare to historical levels and to the broader biotech sector?
Are there any new data or milestones for the lead investigational medicine, zorevunersen, in Dravet syndrome?
What is the anticipated timeline for filing the next IND or seeking regulatory approval for zorevunersen?
How does the current cash runway compare to previous expectations, and will additional financing be required?
Will management provide updated guidance for the remainder of 2025, including R&D spend and operating expenses?
What were the key financial metrics reported for Q2 2025, such as revenue, net loss, and cash on hand?
What are the projected market size and potential pricing for a disease‑modifying treatment for Dravet syndrome?
Did management address any recent share repurchase activity or dividend policy?